with type 2 diabetes mellitus, a well-known risk factor for CAD, had been identified by GWAS in a distinct LD block from the 9p21 CAD core block. Taken together, it is likely that variants at distinct LD blocks in the 9p21 region might have specific functions that link to different clinical conditions. 18, 19 Using case-control studies (CAD or MI versus CAD-free controls), we replicated CAD and MI associations for 24 SNPs and haplotype groups extracted from these variants at an expanded interval spanning 500 kb at 9p21. Furthermore, we investigated whether these genetic variants affected different phenotypes of CAD, including the initial age of symptomatic CAD, the number of diseased vessels, and the prevalence of MI among patients with angiographic CAD.
Methods

Ottawa Heart Genomics Study Subjects
The Ottawa Heart Genomics Study (OHGS) was designed to genomewide map susceptibility loci for CAD in large sample sizes. Details of the study have been described previously. 15, 20 As part of the OHGS, 5211 patients of white ancestry were recruited from the University of Ottawa Heart Institute (UOHI) coronary catheterization laboratory between 2006 and 2010. All participants underwent a coronary angiography, and the angiograms were reviewed by 2 independent angiographers. Any stenosis >50% in an epicardial coronary vessel of interest or in one of its major branches was recorded. For vessel scoring, ramus intermedius lesions were attributed to the circumflex system. The subjects who had a stenosis of ≥50% in ≥1 epicardial vessel were classified to the angiographic CAD group. According to the number of diseased vessels, 1-, 2-, and 3-vessel disease was defined. In addition, 2593 asymptomatic elderly individuals (CADfree, >60 years of age) who visited the lipid clinic at the UOHI were recruited into the control group for the OHGS. Subjects with a history of diabetes mellitus were excluded from the study.
Data, including age, sex, smoking, history of MI, medications on hypertension, and use of cholesterol-lowering drugs, were collected using a questionnaire. Initial age of symptomatic CAD was defined according to the date when the first clinical event (chest pain, MI, clinical interventions, and so on) was recorded. The duration of disease was the years between initial age of symptomatic CAD and the age of consent of angiography. MI was diagnosed according to the World Health Organization criteria. The patients were considered smokers if they were either past or present smokers. Weight and height were recorded, and body mass index was calculated (kg/m 2 ). The present analyses included 2352 patients with angiographic CAD and 2116 asymptomatic controls for whom complete data on the coronary angiogram record for cases and GWAS genotyping were available. Unlike previously reported OHGS studies, 15, 20 the subjects in the present study were only recruited from UOHI. There was no age criterion used to define cases, and symptomatic controls with minimal disease burden (stenosis <30%) defined by angiography were excluded. The case-control (CAD versus CAD-free control) study was designed to replicate the GWAS findings in the OHGS population. Further analyses in angiographic CAD cases explored the associations between the genetic variants and different clinical phenotypes of CAD. All study participants provided written informed consent, and the study was approved by the Research Ethics Board of the UOHI.
Cleveland Clinic GeneBank Subjects (Replication Cohort)
The Cleveland Clinic GeneBank (CCGB) is a large and wellcharacterized clinical repository with blood samples and clinical and longitudinal data comprised from consenting subjects undergoing elective diagnostic cardiac catheterization. Details of the study have been described previously. 15 As a collaborator of the OHGS, 1551 samples of white ancestry who had no history of diabetes mellitus and ≥1 epicardial stenosis >50% by 55 years of age for men and 65 years of age for women were genotyped using Affymetrix 6.0 at the UOHI. One thousand three hundred eighty-five subjects who had complete data from GWAS genotyping and the variable history of MI were included in the final analyses. All GeneBank participants gave written informed consent, and the Institutional Review Board of the Cleveland Clinic approved the study protocol.
Sample Genotyping
Blood was drawn for genetic analyses. DNA was purified from peripheral blood lymphocytes, and all samples were genotyped using the Affymetrix 500K, 6.0, and axiom chips (Affymetrix, Santa Clara, CA) at the John and Jennifer Ruddy Cardiovascular Genetics Centre at the UOHI. Genotyping quality control has been described previously. 15, 20 Briefly, SNPs were excluded if its Hardy-Weinberg equilibrium exact test P value in the control group was <0.001 and its call rate was <90%. Removal of individuals of non-European origin was performed using Eigenstrat. SNPs were included in the analyses only if they fell within 250 kbp of a tagSNP (rs1333049) at the 9p21 locus identified.
Statistical Analysis
The continuous variables are presented as mean±SD. Differences between cases and controls were examined with the χ 2 test for categorical variables and Student t test and 1-way ANOVA for the continuous variables. These statistical analyses were 2-sided and performed with the statistical software SAS (version 9.2.0.0, SAS Institute Inc, Cary, NC). P<0.05 were considered statistically significant. An LD plot was created with Haploview software, 21 and the blocks were generated using a custom procedure with confidence interval minima for strong LD set at 0.7 (lower) and 0.95 (upper), upper confidence interval maximum for strong recombination set at 0.9, and fraction of strong LD in informative comparisons set at >0.95; markers with a frequency <0.05 were excluded. The haplotypes based on SNPs at each block were imputed using the standard expectationmaximization algorithm as implemented in PLINK. 22 The associations between individual SNPs or haplotypes and clinical phenotypes were examined in PLINK using linear or logistical regression analyses, and the haplotype omnibus test was used to jointly estimate all haplotype effects at that position. The covariates for the analyses included age, sex, body mass index, smoking, MI, duration of disease, hypertension medications, and cholesterol-lowering drugs. Only the covariates that were significantly associated with the phenotypes in univariate analyses were included in multiple regression models. Nominal statistical significance of P<0.05 was adjusted using a Bonferroni multiple testing correction, setting a new statistical significance threshold at P<0.002 (0.05/24) for single SNPs and P<0.017 (0.05/3) for haplotype analyses.
Results 9p21 Associations With Angiographic CAD/MI (n=4468; Angiographic CAD Versus CAD-Free Control) in the OHGS
The characteristics of the OHGS population (n=4468) are shown in Tables 1 and 2. The subjects in the CAD-free control group were older and had a lower body weight compared with patients with angiographic CAD. More men were randomly enrolled in the angiographic CAD group, and the prevalence of smoking and antihypertensive medications and the use of cholesterol-lowering drugs were significantly higher in the case group than the control group. The proportion of patients with CAD who have ever smoked (72%) in the present study is comparable with proportions reported in several other studies. 23, 24 As for present smokers, these represented 21.6% of CAD cases. In addition, the mean of the initial age of symptomatic CAD was 58±12 years, and the duration of the disease was 5.2±7.5 years among patients with angiographic CAD (n=2352).
Twenty-four genotyped SNPs at the expanded 9p21 interval (physical position between 21 879 503 and 22 375 503) passed quality control. As shown in the Figure, 24 genotyped SNPs were clustered in 4 haplotype blocks in the OHGS population. Some of the SNPs that predispose to CAD/MI around blocks 1 and 2 were previously identified in GWAS. [8] [9] [10] In the present study, 7 SNPs were significantly associated with angiographic CAD after adjusting for sex, smoking, body mass index, and use of antihypertensive and cholesterol-lowering medications (Table 3 ). Because the 24 SNPs were included in the analyses, we set a statistical significance threshold of 0.002 (0.05/24). We also tested the association after CAD patients with MI (CADMI + ) were excluded from the case group (n=3368; CADMI − versus ctrl), and the results remained the same (Table 3 ). However, the associations were borderline significant when the case group only included CAD with MI (n=3216; CADMI + versus ctrl; Table 3 ).
Haplotype reconstruction resulted in 3 haplotypes with frequency >1% at block 1 (38.1% GCCG, 2.4% GCTA, and 58.2% AGTA), 4 at block 2 (44.5% CAAAAG, 1.4% CAAGAG, 1.9% TGGGCG, and 50% TGGGCC), 2 at block 3 (16.1% GC and 83.1% AT), and 3 at block 4 (30.6% TT, 15.4% GC, and 54% TC). The distribution of the 25 haplotype combinations at blocks 1 and 2 at the 9p21 locus is shown in Table 4 . In the OHGS, among CAD cases who are homozygous carriers of the haplotype AGTA at block 1, 52% were homozygous for the TGGGCC haplotype of block 2, whereas only 3.7% were homozygous for the CAAAAG haplotype of block 2. Interestingly, and conversely, among homozygous carriers of the GCCG haplotype of block 1, 3.9% were homozygous for the TGGGCC haplotype of block 2 and 55% were homozygous for the CAAAAG haplotype of block 2. The effect of the haplotypes for CAD/MI was estimated under the additive model. P<0.013 (0.05/4) were considered statistically significant for haplotype analyses. Using a logistic regression model with the aforementioned covariates, we found that the haplotype TGGGCC at block 2 was an independent determinant of angiographic CAD (CAD versus CAD-free control; n=4468; odds ratio=1.35 [95% confidence interval, 1.32-1.39]; P=1.76×10 -6 ). In contrast, the haplotype CAAAAG had a protective effect against CAD (odds ratio=0.75 [95% confidence interval, 0.73-0.77]; P=5.33×10 -6 ). The same analyses were performed when the patients with MI were excluded from the case group (CADMI − versus CAD-free control; n=3368), and the associations with CAD remained strong. When the CAD case group only consisted of patients with MI (CADMI + versus CAD-free control; n=3216), the associations with MI were borderline significant after adjusting for the same covariates (odds ratio=1.28 [95% confidence interval, 1.21-1.35]; P=0.0025 for TGGGCC; odds ratio=0.775 [95% confidence interval, 0.734-0.818]; P=0.0024 for CAAAAG). No association of the haplotypes at blocks 1, 3, and 4 was observed with CAD or MI compared with CAD-free controls. Table 2 shows the clinical characteristics of all patients with angiographic CAD (n=2352) stratified by MI or 3-vessel disease. Of the patients, 46.8% (CADMI + ; n=1100) had a history of MI and were younger but had higher prevalence of smoking and use of cholesterol-lowering medications than the patients without MI (CADMI − ; n=1252). They also had a longer history of CAD and more severe vessel disease compared with CADMI − . In addition, the number of diseased vessels was significantly increased with age, male sex, longer duration of disease, and higher prevalence of hypertension.
9p21 Association With Initial Age of Symptomatic CAD, the Number of Diseased Vessels, and MI (n=2352; Angiographic CAD Patients) in the OHGS
The associations between the 24 genotyped SNPs and different phenotypes of CAD are shown in Table 3 . The 7 SNPs around block 2 of the 9p21 locus were significantly associated with early onset of CAD but not with 3-vessel disease and prevalent MI. In contrast, the 4 SNPs around block 1 significantly predicted MI among patients with angiographic CAD.
Only 1 SNP (rs643319) showed an association with early initiation of disease and 3-vessel disease. All results were adjusted for the covariates as mentioned before.
The results of haplotype analyses are shown in Table 5 . The haplotypes at block 2 were significantly associated with the initial age of symptomatic CAD and the number of diseased vessels. The initial age of CAD for homozygote carriers of the TGGGCC haplotype (n=644; 57.7±11.0 years) occurred 3 years sooner than for patients homozygous for the CAAAAG haplotype (n=348; 60.7±11.3 years; P<0.00005; Student t test), and TGGGCC carriers had disease that was more severe. In addition, there was no relationship between the haplotypes at block 2 and the prevalence of MI among patients with CAD. In contrast, block 1 haplotype GCCG upstream of block 2 was associated with risk for MI, whereas its complementary haplotype AGTA was protective for MI only among patients with angiographic CAD. Surprisingly, despite being a risk haplotype for MI, the haplotype GCCG was significantly associated with less severe vessel disease.
Replication of Associations With MI in CCGB
The characteristics of CCGB patients (n=1385) are given in Table I in the online-only Data Supplement. This cohort consists of patients with premature CAD with high exposure to traditional risk factors. Compared with non-MI, patients with MI had earlier onset and longer duration of disease. In addition, male sex, smoking, antihypertensive medications, and use of cholesterol-lowering drugs were significantly pronounced among patients with MI. Twenty-two of the 24 SNPs passed quality control in the CCGB. Twenty-two genotyped SNPs were clustered in 4 haplotype blocks that were identical in the OHGS (LD plot not shown). The haplotype frequencies of each block are shown in Table II in the online-only Data Supplement. The distribution of the 25 combinations of the haplotypes at blocks 1 and 2 of the 9p21 locus is shown in Table 4 . The combinations of the 4 homozygous haplotypes at blocks 1 and 2 showed a similar pattern as the CAD group of the OHGS. Replication of MI association with individual SNPs or each haplotype is shown in Table II in the online-only Data Supplement. Four SNPs around haplotype block 1 reached statistical significance for replication. The haplotype GCCG from block 1 increased the risk for MI, whereas its complementary haplotype (AGTA) lowered the risk of MI among the CCGB patients. These results in CCGB were comparable with those of patients with angiographic CAD in the OHGS. †Statistical model: SNP, duration of symptomatic CAD, sex, antihypertensive medication, and the prevalence of MI were entered as predictors into a multiple logistic regression model. Three-vessel disease was coded: 1 for 1-and 2-vessel disease and 2 for 3-vessel disease.
‡Statistical model: SNP, duration of symptomatic CAD, smoking, and use of cholesterol-lowering drugs were entered as predictors into a multiple logistic regression model.
Discussion
In the present study, we identified 2 haplotype blocks at 9p21, certain haplotypes at 1 block that associate with the phenotype of angiographic CAD and haplotypes at another that associate with MI among cases of preexisting CAD. CAD is a chain of events: at the initial age of symptomatic CAD, the number of CAD indicates coronary artery disease; and MI, myocardial infarction. *Statistical model: haplotype, sex, body mass index, smoking, antihypertensive medication, and use of cholesterol-lowering drugs were entered as predictors into the multiple linear regression model. †P values were obtained by jointly estimating all haplotype effects at that position. ‡Statistical model: haplotype, duration of symptomatic CAD, sex, antihypertensive medication, and the prevalence of MI were entered as predictors into a multiple logistic regression model. Three-vessel disease was coded: 1 for 1-and 2-vessel disease and 2 for 3-vessel disease.
§Statistical model: haplotype, duration of symptomatic CAD, smoking, and use of cholesterol-lowering drugs were entered as predictors into a multiple logistic model. #Frequencies for the major homozygote haplotypes.
diseased coronary vessels and prevalent MI are all detectable phenotypes along the chain leading to end-stage CAD. Multiple SNPs in tight LD at the 9p21 locus have been identified with the risk of CAD or MI by GWAS. [8] [9] [10] 25 In the present study, we dissected the associations between the haplotypes at distinct LD blocks of an expanded 9p21 interval and specific clinical phenotypes of CAD. First, we used a case-control (CAD versus CAD-free control) study design to replicate the GWAS findings in the OHGS population, and 7 of 24 SNPs in a commonly reported core block of the 9p21 locus were significantly associated with CAD or MI. Compared with patients with MI, the patients without a history of MI showed a stronger association with the variants in this block. These results were completely in concert with the results from previous GWAS, allowing for comparison between the results from GWAS and more comprehensive analyses in the present study that might produce more sound results.
Previously, we reported a dose response of a tag SNP (rs1333049) at the 9p21 locus with CAD severity in patients with either early-onset CAD (n=950) or older patients with CAD (n=764). 15 Recruitment continued until 2010, and the sample size expanded. In the present analyses, we included all patients with angiographic CAD (n=2352) who were randomly recruited from our catheterization laboratory for the OHGS. The present results confirmed our previous observations that the 7 SNPs, including the rs1333049 and the haplotype group (TGGGCC) made up of the risk alleles at this region, were significantly associated with severity of vessel disease. Furthermore, we found that patients with 2 copies of the risk haplotype (TGGGCC) initiated symptomatic CAD 3 years earlier than patients with its complementary haplotype (CAAAAG). This result was consistent with the data from a previous study in New Zealand by Kathiresan et al. 26 They investigated the association of a tag SNP (rs1333049) with the age of onset of CAD in 2 CAD cohorts. They reported that the patients homozygous for risk C allele developed CAD ≈2 to 3 years earlier than the rest of the patients. Our study using linked SNP groups was more informative than the 1 using an individual SNP, suggesting that subjects with the risk haplotype that arises from variants at this LD block (block 2 in the present study) acquire greater atherosclerotic burden at an earlier age in life. Our data also supported a recent meta-analysis, which included 22 reports with 47 distinct data sets, showing a stronger effect of the variants at the 9p21 locus at an earlier age of CAD onset. 3 In the present study, the prevalence of MI was higher in early-onset patients who had more severe CAD. Although the variants at the core block of the 9p21 locus (block 2) predicted an early onset of CAD and more severe disease, the variants in this block were not associated with the prevalence of MI with patients with preexisting CAD. In contrast, these risk alleles trended toward a protection from MI among the patients with CAD. These findings were replicated in an independent premature CAD cohort (CCGB). Consistent with our findings, several studies also addressed the issue that the variants in this block did not predict MI within patients with established CAD, but they were significantly associated with MI when the controls were CAD-free. [15] [16] [17] 27 CAD is a broad definition, and its basic feature is coronary atherosclerosis. MI is 1 of the major adverse outcomes of CAD, and it is usually preceded by CAD. The most common cause of MI is vulnerable atherosclerotic plaque rupture and thrombosis. However, only a few with coronary atherosclerosis finally develop MI. [28] [29] [30] Therefore, the association between the variants at 9p21 and MI observed in our and previous case-control (CAD-free control) studies was probably a consequence of increased atherosclerotic burden related to these variants rather than a greater propensity for actual precipitation of MI among these patients. In contrast, the lack of association with MI observed among patients with established CAD suggested that the variants in this LD block (block 2) were not involved in the biological pathways that trigger vulnerable plaque rupture and thrombosis.
Consistent with our results, a recent study by Gong et al 27 also showed that the variants at this LD block of the 9p21 locus (block 2) were not associated with higher risk for longterm adverse outcomes among patients with preexisting CAD in 2 independent cohorts. They suggested that the variants at a less commonly reported LD block at the 9p21 locus (block 1 in the present study) predicted prognosis among patients with established CAD. In the present study, we observed a similar finding in which the haplotype (GCCG) increased the risk for MI, whereas its complementary haplotype (AGTA) provided protection from MI among patients with angiographic CAD. The finding was also replicated in patients with premature CAD from the CCGB study. Potential mechanisms that account for this finding are unknown. However, a study by Musunuru et al 31 reported that SNPs in this LD block were significantly associated with increased platelet reactivity in 3 independent CAD cohorts. Platelets are crucial elements in the process of arterial thrombosis. Platelet adhesion and aggregation might be a major cause of acute cardiovascular events after plaque rupture. 32 Therefore, it is possible that the effect of the risk alleles at this LD block (block 1) contributes to higher incidence of MI among patients with atherosclerosis by regulating platelet reactivity. Despite being a risk for prevalent MI in patients with preexisting CAD, the haplotype (GCCG) at LD block 1 seems to protect from disease severity. This apparently paradoxical finding was also observed in LD block 2, for which the risk haplotype (TGGGCC) for the initiation and severity of disease had a protective trend for prevalent MI among patients with established CAD. We examined the distribution of 25 combinations of haplotypes in blocks 1 and 2 in CAD cases (n=2345) and CAD-free controls (n=2106) from the OHGS, as well as patients with premature CAD (n=1369) from CCGB. We found that in more than half of the patients who were homozygous for the MI protective haplotype at block 1, these were homozygous for the CAD risk haplotype of block 2, whereas those who were homozygous for the MI risk haplotype of block 1 were also homozygous for the CAD protective haplotype of block 2. This apparently paradoxical combination of CAD and MI risk haplotypes was seen in both CAD case and the CAD-free control groups, indicating that this pattern reflects distribution of the haplotypes in our populations rather than their segregation according to disease. The variants at the distinct LD blocks of the 9p21 region probably represent different genetic signals that exclusively function on specific biological pathways related to different clinical phenotypes of CAD, 1 haplotype that is proatherogenic (block 2) and the other that is prothrombotic (block 1) among cases of clinically significant CAD. This is the first time that we have addressed the issue of the combination of the haplotypes at the 2 distinct LD blocks of the 9p21 locus in the OHGS population, and it was replicated in a premature the CAD cohort from the CCGB. It will be interesting to see whether our findings can be replicated in other large-scale studies.
Our study has some limitations. Because of the OHGS study design, people with diabetes mellitus were excluded from the study to limit confounding by diabetes mellitus and to discover genetic variants that predispose uniquely to CAD. 15 Therefore, further studies will be required to confirm whether our results apply to the general population. Another potential factor is the older age of controls in the OHGS study design. 15, 20 The OHGS deliberately chose elderly asymptomatic controls to facilitate the discovery of alleles that predispose to CAD. However, the primary findings of our study, namely the association of haplotypes of block 1 with MI and block 2 with age of CAD onset and severity, apply to CAD cases and should not be influenced by the older age of the controls. The present analyses in CAD cases of the OHGS are based on cross-sectional data, and an earlier onset of disease conferred by the 9p21 risk alleles might cause a greater burden of atherosclerosis at similar ages at the time of recruitment. Although our analyses were adjusted for duration of disease, further prospective studies, as reported by others, 23, 24 to confirm the impact of the 2 haplotypes at 9p21 on the progression of CAD and subsequent events are warranted.
Conclusions
The present study suggests that the variants at distinct LD blocks of the 9p21 region were exclusively associated with different phenotypes of CAD. The variants at LD block 2 seem to predispose to atherosclerosis initiation and progression, whereas those at block 1 predict plaque rupture and thrombosis among patients with established CAD. This novel finding will enable us to explore the distinct biological mechanisms underlying the risk for CAD and MI conferred by the 9p21 variants. Importantly, these novel variants will need to be considered in genetic models of risk stratification to predict acute events.
